aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
Volume 1.02M
Average 2.29M
ATYR Operating Income
Profit from core operations after operating expenses, before interest and taxes.
aTyr Pharma, Inc.NASDAQ: ATYR
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$11.44M, compared with -$15.77M a year earlier. Trailing-twelve-month operating income was -$73.29M.
Context
- Operating income amounted to 40856.3% of revenue in FY2025, up 11956.7 pp from a year earlier.
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 6 analysts of -$40.94M (+47.3%) for the fiscal year ending Dec 2026, a step up from the -14.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$11.44M+22.7% QoQ
- Last fiscal yearDec 2025
- -$77.63M-14.3% YoY
- LTMMar 2026
- -$73.29M-9.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.5% | — | — |
| 1 year | -14.3% | +47.3% | +61.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (77.63M) USD
- Year-over-year change
- -14.3%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (77.63M) | -14.3% |
| FY2024 | 2024-12-31 | (67.91M) | -23.7% |
| FY2023 | 2023-12-31 | (54.92M) | -18.3% |
| FY2022 | 2022-12-31 | (46.4M) | -36.4% |
| FY2021 | 2021-12-31 | (34.02M) | — |
Operating Income vs competitors
How ATYR compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -9.3% is the lowest of 8, against a peer median of +11.6%.
- Operating income amounts to 38573.7% of revenue for ATYR, versus a peer median of 86.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | -CA$11.99M CAD | +23.1% | — | 65.3% |
| LTM Mar 2026 | -$29.97M USD | +3.0% | — | — | |
| LTM Mar 2026 | -$39.11M USD | +11.3% | — | 86.8% | |
| LTM Mar 2026 | -$52.03M USD | +2.4% | — | 1322.6% | |
| LTM Mar 2026 | -$60.34M USD | +23.7% | — | — | |
| LTM Mar 2026 | -$73.29M USD | -9.3% | — | 38573.7% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.35M USD | +11.6% | — | — |
| LTM Mar 2026 | -$91.17M USD | +33.2% | — | — | |
| Peer median (excluding ATYR) | — | +11.6% | — | 86.8% | |
Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 10.39M | 353K | 235K | 190K |
| Cost of Revenue | 1.3M | 1.7M | 0 | 0 | 1.55M |
| Gross Profit | (1.3M) | 8.69M | 353K | 235K | (1.36M) |
| Gross Margin | — | 83.7% | 100.0% | 100.0% | -717.4% |
| Research & Development | 23.26M | 42.81M | 42.29M | 54.37M | 60.22M |
| Selling, General & Admin | 10.75M | 12.29M | 12.98M | 13.78M | 17.6M |
| Operating Expenses | 32.71M | 55.1M | 55.27M | 68.15M | 76.26M |
| Depreciation & Amortization | 1.3M | 1.7M | 2.74M | 1.54M | 1.55M |
| EBITDA | (32.47M) | (43.65M) | (47.66M) | (62.48M) | (72.57M) |
| EBITDA Margin | — | -420.3% | -13500.3% | -26588.1% | -38192.1% |
| Operating Income | (34.02M) | (46.4M) | (54.92M) | (67.91M) | (77.63M) |
| Operating Margin | — | -446.8% | -15557.8% | -28899.6% | -40856.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 238K | 1.06M | 4.52M | 3.89M | 3.51M |
| Income Before Tax | (33.78M) | (45.34M) | (50.4M) | (64.02M) | (74.12M) |
| Pre-Tax Margin | — | -436.6% | -14276.8% | -27243.4% | -39009.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.77M) | (45.34M) | (50.39M) | (64.02M) | (74.12M) |
| Net Margin | — | -436.5% | -14274.5% | -27243.8% | -39009.5% |
| EPS (Basic) | (1.77) | (1.60) | (0.94) | (0.86) | (0.80) |
| EPS (Diluted) | (1.77) | (1.60) | (0.94) | (0.86) | (0.80) |
| Weighted Avg Shares | 19.08M | 28.42M | 53.61M | 74.26M | 92.99M |
| Weighted Avg Shares (Diluted) | 19.08M | 28.42M | 53.61M | 74.26M | 92.99M |
aTyr Pharma, Inc.
NASDAQ:ATYR
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.